Salvat
Focus: Salvat is a mid-cap specialty biotech focused on small-molecule therapies in ophthalmology and immunology, headquartered in Miami with 201–500 employees. The company is heavily dependent on its approved otic/ophthalmic portfolio, particularly OTOVEL.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Employees
201-500
Open Jobs
18+18 this month
Growing — net +18 jobs in 30d
24 jobs added vs 6 removed. Steady team buildout.
Should You Work at Salvat?
AI assessmentSalvat offers pipeline depth and otic/ophthalmic focus appeal, but extreme revenue concentration, near-term patent cliff, and absence of current hiring create moderate-to-high career risk unless pipeline delivers near-term approvals.
Why Work Here
- Late-stage pipeline with 10 Phase 3 programs across otic, ophthalmic, and specialty indications suggesting near-term clinical catalysts
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
10 Phase 3+
LOE Risk
1 in 5yr
OTOVEL
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$4K (Part D)Stable
Peak3.8yr
Only revenue-generating product and sole driver of company finances; peak sales phase but patent cliff arrives in 6 years.
Help build intelligence for Salvat
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.